

Suzanne Oparil

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5986888/publications.pdf>

Version: 2024-02-01

257
papers

52,809
citations

23500

58
h-index

1280

225
g-index

267
all docs

267
docs citations

267
times ranked

37451
citing authors

#	ARTICLE	IF	CITATIONS
1	The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>. JAMA - Journal of the American Medical Association, 2003, 289, 2560.	3.8	18,097
2	2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults. JAMA - Journal of the American Medical Association, 2014, 311, 507.	3.8	6,625
3	Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet, The, 2002, 359, 995-1003.	6.3	4,917
4	A Randomized Trial of Intensive versus Standard Blood-Pressure Control. New England Journal of Medicine, 2015, 373, 2103-2116.	13.9	4,880
5	A Controlled Trial of Renal Denervation for Resistant Hypertension. New England Journal of Medicine, 2014, 370, 1393-1401.	13.9	1,848
6	Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years. JAMA - Journal of the American Medical Association, 2016, 315, 2673.	3.8	991
7	Feasibility of Treating Prehypertension with an Angiotensin-Receptor Blocker. New England Journal of Medicine, 2006, 354, 1685-1697.	13.9	854
8	Essential Hypertension. Circulation, 2000, 101, 329-335.	1.6	829
9	Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia. JAMA - Journal of the American Medical Association, 2019, 321, 553.	3.8	786
10	Hypertension. Nature Reviews Disease Primers, 2018, 4, 18014.	18.1	636
11	Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet, The, 2018, 391, 2335-2345.	6.3	526
12	Pathogenesis of Hypertension. Annals of Internal Medicine, 2003, 139, 761.	2.0	501
13	Effects of Dietary Sodium Reduction on Blood Pressure in Subjects With Resistant Hypertension. Hypertension, 2009, 54, 475-481.	1.3	474
14	Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. European Heart Journal, 2015, 36, 219-227.	1.0	458
15	Sex hormones and hypertension. Cardiovascular Research, 2002, 53, 688-708.	1.8	453
16	Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet, The, 2007, 370, 221-229.	6.3	432
17	The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: The Systolic Blood Pressure Intervention Trial (SPRINT). Clinical Trials, 2014, 11, 532-546.	0.7	408
18	The Relationship Between Visit-to-Visit Variability in Systolic Blood Pressure and All-Cause Mortality in the General Population. Hypertension, 2011, 57, 160-166.	1.3	397

#	ARTICLE	IF	CITATIONS
19	Effects of Intensive BP Control in CKD. Journal of the American Society of Nephrology: JASN, 2017, 28, 2812-2823.	3.0	364
20	Preeclampsiaâ€™ Pathophysiology and Clinical Presentations. Journal of the American College of Cardiology, 2020, 76, 1690-1702.	1.2	305
21	Association of Intensive vs Standard Blood Pressure Control With Cerebral White Matter Lesions. JAMA - Journal of the American Medical Association, 2019, 322, 524.	3.8	285
22	Direct In Vivo Evidence Demonstrating Neointimal Migration of Adventitial Fibroblasts After Balloon Injury of Rat Carotid Arteries. Circulation, 2000, 101, 1362-1365.	1.6	256
23	Characterization of Resistant Hypertension<subitle>Association Between Resistant Hypertension, Aldosterone, and Persistent Intravascular Volume Expansion</subitle>. Archives of Internal Medicine, 2008, 168, 1159.	4.3	254
24	New Approaches in the Treatment of Hypertension. Circulation Research, 2015, 116, 1074-1095.	2.0	233
25	Treatment for Mild Chronic Hypertension during Pregnancy. New England Journal of Medicine, 2022, 386, 1781-1792.	13.9	215
26	Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. Journal of the American College of Cardiology, 2003, 41, 1148-1155.	1.2	214
27	Final Report of a Trial of Intensive versus Standard Blood-Pressure Control. New England Journal of Medicine, 2021, 384, 1921-1930.	13.9	214
28	Role of the Renal Sympathetic Nerves in the Development and Maintenance of Hypertension in the Spontaneously Hypertensive Rat. Journal of Clinical Investigation, 1980, 66, 971-978.	3.9	197
29	Blood Pressure Measurement in SPRINT (Systolic Blood Pressure Intervention Trial). Hypertension, 2018, 71, 848-857.	1.3	190
30	Impact of Renal Denervation on 24-Hour Ambulatory Blood Pressure. Journal of the American College of Cardiology, 2014, 64, 1071-1078.	1.2	164
31	Refractory Hypertension: Definition, Prevalence, and Patient Characteristics. Journal of Clinical Hypertension, 2012, 14, 7-12.	1.0	160
32	Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes. New England Journal of Medicine, 2017, 377, 733-744.	13.9	160
33	Cost-Effectiveness of Intensive versus Standard Blood-Pressure Control. New England Journal of Medicine, 2017, 377, 745-755.	13.9	157
34	Rapid Reversal of Left Ventricular Hypertrophy and Intracardiac Volume Overload in Patients With Resistant Hypertension and Hyperaldosteronism. Hypertension, 2010, 55, 1137-1142.	1.3	137
35	Hypertension in Women. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1862-1866.	1.8	127
36	Severity of Obstructive Sleep Apnea is Related to Aldosterone Status in Subjects with Resistant Hypertension. Journal of Clinical Sleep Medicine, 2010, 06, 363-368.	1.4	123

#	ARTICLE	IF	CITATIONS
37	Treatment of Resistant and Refractory Hypertension. <i>Circulation Research</i> , 2019, 124, 1061-1070.	2.0	117
38	Association of Clinical and Social Factors With Excess Hypertension Risk in Black Compared With White US Adults. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1338.	3.8	116
39	Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality. <i>Journal of the American Society of Hypertension</i> , 2014, 8, 405-413.	2.3	113
40	12-Month Blood Pressure Results of Catheter-Based Renal Artery Denervation for Resistant Hypertension. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1314-1321.	1.2	103
41	Salt and cardiovascular disease: insufficient evidence to recommend low sodium intake. <i>European Heart Journal</i> , 2020, 41, 3363-3373.	1.0	103
42	VEGF nanoparticles repair the heart after myocardial infarction. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2018, 314, H278-H284.	1.5	101
43	Refractory Hypertension. <i>Hypertension</i> , 2015, 66, 126-133.	1.3	98
44	Medroxyprogesterone Attenuates Estrogen-Mediated Inhibition of Neointima Formation After Balloon Injury of the Rat Carotid Artery. <i>Circulation</i> , 1996, 94, 2221-2227.	1.6	94
45	Effect of Intensive Blood Pressure Treatment on Heart Failure Events in the Systolic Blood Pressure Reduction Intervention Trial. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	88
46	SPRINT Trial Results. <i>Hypertension</i> , 2016, 67, 263-265.	1.3	79
47	Effects of Intensive Systolic Blood Pressure Lowering on Cardiovascular Events and Mortality in Patients With Type 2 Diabetes Mellitus on Standard Glycemic Control and in Those Without Diabetes Mellitus: Reconciling Results From ACCORD BP and SPRINT. <i>Journal of the American Heart Association</i> , 2018, 7, e009326.	1.6	79
48	The Association Between Antihypertensive Medication Nonadherence and Visit-to-Visit Variability of Blood Pressure. <i>Hypertension</i> , 2016, 68, 39-45.	1.3	77
49	Chronic hypertension in pregnancy. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 222, 532-541.	0.7	76
50	Association of Blood Pressure Classification Using the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline With Risk of Heart Failure and Atrial Fibrillation. <i>Circulation</i> , 2021, 143, 2244-2253.	1.6	75
51	Accuracy of Blood Pressure Measurement Devices in Pregnancy. <i>Hypertension</i> , 2018, 71, 326-335.	1.3	74
52	Sexually Dimorphic Response of the Balloon-Injured Rat Carotid Artery to Hormone Treatment. <i>Circulation</i> , 1997, 95, 1301-1307.	1.6	70
53	Low Sodium Intake " Cardiovascular Health Benefit or Risk?. <i>New England Journal of Medicine</i> , 2014, 371, 677-679.	13.9	69
54	Prevention, Diagnosis, and Management of Hypertensive Disorders of Pregnancy: a Comparison of International Guidelines. <i>Current Hypertension Reports</i> , 2020, 22, 66.	1.5	67

#	ARTICLE	IF	CITATIONS
55	The technical report on sodium intake and cardiovascular disease in low- and middle-income countries by the joint working group of the World Heart Federation, the European Society of Hypertension and the European Public Health Association. <i>European Heart Journal</i> , 2017, 38, ehw549.	1.0	65
56	Gender and Blood Pressure. <i>Journal of Clinical Hypertension</i> , 2005, 7, 300-309.	1.0	63
57	Hypertension in Women. <i>Hypertension</i> , 2017, 70, 19-26.	1.3	63
58	Is Blood Pressure Control for Stroke Prevention the Correct Goal?. <i>Stroke</i> , 2015, 46, 1595-1600.	1.0	62
59	Increased Dietary Sodium Is Related to Severity of Obstructive Sleep Apnea in Patients With Resistant Hypertension and Hyperaldosteronism. <i>Chest</i> , 2013, 143, 978-983.	0.4	61
60	Incident Cardiovascular Disease Among Adults With Blood Pressure \leq 140/90 mmHg. <i>Circulation</i> , 2017, 136, 798-812.	1.6	60
61	Cognitive Function and Kidney Disease: Baseline Data From the Systolic Blood Pressure Intervention Trial (SPRINT). <i>American Journal of Kidney Diseases</i> , 2017, 70, 357-367.	2.1	60
62	Refractory Hypertension. <i>Hypertension</i> , 2016, 67, 1085-1092.	1.3	59
63	Association of 3 Different Antihypertensive Medications With Hip and Pelvic Fracture Risk in Older Adults. <i>JAMA Internal Medicine</i> , 2017, 177, 67.	2.6	59
64	Intensive vs Standard Blood Pressure Control in Adults 80 Years or Older: A Secondary Analysis of the Systolic Blood Pressure Intervention Trial. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 496-504.	1.3	59
65	Estrogen Effects on Vascular Inflammation Are Age Dependent. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 1477-1485.	1.1	57
66	Orthostatic Hypotension, Cardiovascular Outcomes, and Adverse Events. <i>Hypertension</i> , 2020, 75, 660-667.	1.3	57
67	Orthostatic changes in systolic blood pressure among SPRINT participants at baseline. <i>Journal of the American Society of Hypertension</i> , 2016, 10, 847-856.	2.3	56
68	Estrogen Inhibits Vascular Smooth Muscle Cell-Dependent Adventitial Fibroblast Migration In Vitro. <i>Circulation</i> , 1999, 100, 1639-1645.	1.6	55
69	Effect of Chlorthalidone, Amlodipine, and Lisinopril on Visit-to-Visit Variability of Blood Pressure: Results From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. <i>Journal of Clinical Hypertension</i> , 2014, 16, 323-330.	1.0	55
70	Concordance Between Blood Pressure in the Systolic Blood Pressure Intervention Trial and in Routine Clinical Practice. <i>JAMA Internal Medicine</i> , 2020, 180, 1655.	2.6	52
71	Angiotensin Receptor Blocker and Dihydropyridine Calcium Channel Blocker Combinations: An Emerging Strategy in Hypertension Therapy. <i>Postgraduate Medicine</i> , 2009, 121, 25-39.	0.9	51
72	Prevalence of pseudoresistant hypertension due to inaccurate blood pressure measurement. <i>Journal of the American Society of Hypertension</i> , 2016, 10, 493-499.	2.3	50

#	ARTICLE	IF	CITATIONS
73	Long-Term Follow-Up of Participants With Heart Failure in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). <i>Circulation</i> , 2011, 124, 1811-1818.	1.6	49
74	Intensive blood pressure lowering prevents mild cognitive impairment and possible dementia and slows development of white matter lesions in brain: the SPRINT Memory and Cognition IN Decreased Hypertension (SPRINT MIND) study. <i>Blood Pressure</i> , 2018, 27, 247-248.	0.7	47
75	Sex Differences in Hypertension and Stroke Risk in the REGARDS Study. <i>Hypertension</i> , 2019, 74, 749-755.	1.3	47
76	Epicardial Adipose Tissue and Cardiovascular Disease. <i>Current Hypertension Reports</i> , 2019, 21, 36.	1.5	47
77	Women and Hypertension. <i>Cardiology in Review</i> , 2006, 14, 267-275.	0.6	44
78	Blood Pressures and Cardiovascular Homeostasis in Mice Having Reduced or Absent Angiotensin-Converting Enzyme Gene Function. <i>Hypertension</i> , 1997, 30, 128-133.	1.3	43
79	Body Mass Index Predicts 24-Hour Urinary Aldosterone Levels in Patients With Resistant Hypertension. <i>Hypertension</i> , 2016, 68, 995-1003.	1.3	42
80	Cardiovascular effects of estrogen. <i>American Journal of Hypertension</i> , 2001, 14, S186-S193.	1.0	38
81	Mortality and Morbidity During and After the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. <i>Journal of Clinical Hypertension</i> , 2012, 14, 20-31.	1.0	38
82	Mortality and Morbidity During and After Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. <i>Hypertension</i> , 2013, 61, 977-986.	1.3	36
83	An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPPLICITY HTN-3 trial. <i>Journal of the American Society of Hypertension</i> , 2015, 9, 769-779.	2.3	36
84	The use of ambulatory blood pressure monitoring among Medicare beneficiaries in 2007-2010. <i>Journal of the American Society of Hypertension</i> , 2014, 8, 891-897.	2.3	35
85	The J-curve phenomenon revisited again: SPRINT outcomes favor target systolic blood pressure below 120 mmHg. <i>Blood Pressure</i> , 2016, 25, 1-3.	0.7	35
86	Hypertension in Women. , 0, .		35
87	Bradykinin in the Heart. <i>Circulation</i> , 1999, 100, 2305-2307.	1.6	34
88	Rates, amounts, and determinants of ambulatory blood pressure monitoring claim reimbursements among Medicare beneficiaries. <i>Journal of the American Society of Hypertension</i> , 2014, 8, 898-908.	2.3	34
89	Obesity and Pulmonary Hypertension. <i>Current Hypertension Reports</i> , 2018, 20, 99.	1.5	34
90	Visceral Adipose Tissue Accumulation and Residual Cardiovascular Risk. <i>Current Hypertension Reports</i> , 2018, 20, 77.	1.5	34

#	ARTICLE	IF	CITATIONS
91	Genetic Variation in Angiotensin-Converting Enzyme Does Not Prevent Development of Cardiac Hypertrophy or Upregulation of Angiotensin II in Response to Aortocaval Fistula. <i>Circulation</i> , 2001, 103, 1012-1016.	1.6	31
92	O-Linked Γ^2 -N-Acetylglucosamine Modification of A20 Enhances the Inhibition of NF- Γ^{B} (Nuclear Factor- Γ^{B}) Activation and Elicits Vascular Protection After Acute Endoluminal Arterial Injury. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 1309-1320.	1.1	31
93	The Story of the Silent Killer. <i>Current Hypertension Reports</i> , 2020, 22, 72.	1.5	31
94	Blood pressure medication should not be routinely dosed at bedtime. We must disregard the data from the HYGIA project. <i>Blood Pressure</i> , 2020, 29, 135-136.	0.7	31
95	Gender, blood pressure, and cardiovascular and renal outcomes in adults with hypertension from the Systolic Blood Pressure Intervention Trial. <i>Journal of Hypertension</i> , 2018, 36, 904-915.	0.3	30
96	Subgroup Analyses of an Efficacy and Safety Study of Concomitant Administration of Amlodipine Besylate and Olmesartan Medoxomil: Evaluation by Baseline Hypertension Stage and Prior Antihypertensive Medication Use. <i>Journal of Cardiovascular Pharmacology</i> , 2009, 54, 427-436.	0.8	29
97	Refractory Hypertension Is not Attributable to Intravascular Fluid Retention as Determined by Intracardiac Volumes. <i>Hypertension</i> , 2018, 72, 343-349.	1.3	29
98	Out-of-Clinic Sympathetic Activity Is Increased in Patients With Masked Uncontrolled Hypertension. <i>Hypertension</i> , 2019, 73, 132-141.	1.3	29
99	The role of exercise in the reversal of IGF-1 deficiencies in microvascular rarefaction and hypertension. <i>GeroScience</i> , 2020, 42, 141-158.	2.1	28
100	Missing Verification of Source Data in Hypertension Research: The HYGIA PROJECT in Perspective. <i>Hypertension</i> , 2021, 78, 555-558.	1.3	28
101	Enalapril in low-renin essential hypertension. <i>Clinical Pharmacology and Therapeutics</i> , 1983, 34, 297-302.	2.3	26
102	The Calcium Antagonists in the 1990s. <i>American Journal of Hypertension</i> , 1991, 4, 396S-405S.	1.0	26
103	Long-Term Follow-Up of Moderately Hypercholesterolemic Hypertensive Patients Following Randomization to Pravastatin vs Usual Care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (<sc>ALLHAT</sc> <sc>LLT</sc>). <i>Journal of Clinical Hypertension</i> , 2013, 15, 542-554.	1.0	26
104	Effect of Intensive Blood Pressure Reduction on Left Ventricular Mass, Structure, Function, and Fibrosis in the SPRINT-HEART. <i>Hypertension</i> , 2019, 74, 276-284.	1.3	26
105	Results of an Olmesartan Medoxomil-Based Treatment Regimen in Hypertensive Patients. <i>Journal of Clinical Hypertension</i> , 2008, 10, 911-921.	1.0	25
106	Ambulatory Blood Pressure Monitoring in Individuals with HIV: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0148920.	1.1	25
107	Kidney Disease, Intensive Hypertension Treatment, and Risk for Dementia and Mild Cognitive Impairment: The Systolic Blood Pressure Intervention Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2122-2132.	3.0	25
108	Should Patients With Cardiovascular Risk Factors Receive Intensive Treatment of Hypertension to <120/80 mmHg Target?. <i>Circulation</i> , 2016, 134, 1308-1310.	1.6	24

#	ARTICLE	IF	CITATIONS
109	Race-based and sex-based differences in bioactive lipid mediators after myocardial infarction. <i>ESC Heart Failure</i> , 2020, 7, 1700-1710.	1.4	24
110	Apparent Treatment-resistant Hypertension Among Individuals with History of Stroke or Transient Ischemic Attack. <i>American Journal of Medicine</i> , 2015, 128, 707-714.e2.	0.6	23
111	Antihypertensive Medication Adherence and Confirmation of True Refractory Hypertension. <i>Hypertension</i> , 2020, 75, 510-515.	1.3	23
112	Circadian variations in blood pressure and their implications for the administration of antihypertensive drugs: is dosing in the evening better than in the morning?. <i>Journal of Hypertension</i> , 2020, 38, 1396-1406.	0.3	23
113	Coffee and Arterial Hypertension. <i>Current Hypertension Reports</i> , 2021, 23, 38.	1.5	23
114	White-Coat Effect Is Uncommon in Patients With Refractory Hypertension. <i>Hypertension</i> , 2017, 70, 645-651.	1.3	21
115	Risk stratification of sudden cardiac death in hypertension. <i>Journal of Electrocardiology</i> , 2017, 50, 798-801.	0.4	20
116	Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT. <i>Journal of the American Society of Hypertension</i> , 2014, 8, 808-819.	2.3	18
117	Sustained blood pressure control and coronary heart disease, stroke, heart failure, and mortality: An observational analysis of ALLHAT. <i>Journal of Clinical Hypertension</i> , 2019, 21, 451-459.	1.0	18
118	Urinary Biomarkers of Tubular Damage Are Associated with Mortality but Not Cardiovascular Risk among Systolic Blood Pressure Intervention Trial Participants with Chronic Kidney Disease. <i>American Journal of Nephrology</i> , 2019, 49, 346-355.	1.4	18
119	Patterns and Correlates of Baseline Thiazide-Type Diuretic Prescription in the Systolic Blood Pressure Intervention Trial. <i>Hypertension</i> , 2016, 67, 550-555.	1.3	17
120	Migrating Populations and Health: Risk Factors for Cardiovascular Disease and Metabolic Syndrome. <i>Current Hypertension Reports</i> , 2022, 24, 325-340.	1.5	17
121	New 2017 American Heart Association and American College of Cardiology guideline for hypertension in the adults: major paradigm shifts, but will they help to fight against the hypertension disease burden?. <i>Blood Pressure</i> , 2018, 27, 62-65.	0.7	16
122	Prognostic value of myocardial perfusion imaging performed pre-renal transplantation: post-transplantation follow-up and outcomes. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1998-2008.	3.3	16
123	Obesity, Hypertension, and Bariatric Surgery. <i>Current Hypertension Reports</i> , 2020, 22, 46.	1.5	16
124	Potential protective effects of antihypertensive treatments during the Covid-19 pandemic: from inhibitors of the renin-angiotensin system to beta-adrenergic receptor blockers. <i>Blood Pressure</i> , 2021, 30, 1-3.	0.7	16
125	An Update on Refractory Hypertension. <i>Current Hypertension Reports</i> , 2022, 24, 225-234.	1.5	16
126	Correlations of plasma renin activity and aldosterone concentration with ambulatory blood pressure responses to nebivolol and valsartan, alone and in combination, in Hypertension. <i>Journal of the American Society of Hypertension</i> , 2015, 9, 845-854.	2.3	15

#	ARTICLE	IF	CITATIONS
127	Electrocardiographic measures of left ventricular hypertrophy in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. <i>Journal of the American Society of Hypertension</i> , 2016, 10, 930-938.e9.	2.3	15
128	Masked Uncontrolled Hypertension Is Not Attributable to Medication Nonadherence. <i>Hypertension</i> , 2019, 74, 652-659.	1.3	15
129	Lofexidine and clonidine in moderate essential hypertension. <i>Clinical Pharmacology and Therapeutics</i> , 1981, 30, 752-757.	2.3	14
130	Baseline characteristics of African Americans in the Systolic Blood Pressure Intervention Trial. <i>Journal of the American Society of Hypertension</i> , 2015, 9, 670-679.	2.3	14
131	The Global Burden of Disease Study 2015 and Blood Pressure. <i>Blood Pressure</i> , 2017, 26, 1-1.	0.7	14
132	PTH, FGF23, and Intensive Blood Pressure Lowering in Chronic Kidney Disease Participants in SPRINT. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1816-1824.	2.2	14
133	2018 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension. <i>Blood Pressure</i> , 2018, 27, 313-313.	0.7	14
134	Pulse wave velocity and central aortic pressure in systolic blood pressure intervention trial participants. <i>PLoS ONE</i> , 2018, 13, e0203305.	1.1	14
135	Plasma xanthine oxidase activity is related to increased sodium and left ventricular hypertrophy in resistant hypertension. <i>Free Radical Biology and Medicine</i> , 2019, 134, 343-349.	1.3	14
136	Reserpine Substantially Lowers Blood Pressure in Patients With Refractory Hypertension: A Proof-of-Concept Study. <i>American Journal of Hypertension</i> , 2020, 33, 741-747.	1.0	14
137	Weight Reduction for Obesity-Induced Heart Failure with Preserved Ejection Fraction. <i>Current Hypertension Reports</i> , 2020, 22, 47.	1.5	14
138	Spirolactone Reduces Aortic Stiffness in Patients With Resistant Hypertension Independent of Blood Pressure Change. <i>Journal of the American Heart Association</i> , 2021, 10, e019434.	1.6	14
139	Disregard the reported data from the HYGIA project: blood pressure medication not to be routinely dosed at bedtime. <i>Journal of Hypertension</i> , 2020, 38, 2144-2145.	0.3	14
140	Antihypertensive Medication Classes Used among Medicare Beneficiaries Initiating Treatment in 2007-2010. <i>PLoS ONE</i> , 2014, 9, e105888.	1.1	13
141	Targeted Delivery of Pulmonary Arterial Endothelial Cells Overexpressing Interleukin-8 Receptors Attenuates Monocrotaline-Induced Pulmonary Vascular Remodeling. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 1539-1547.	1.1	13
142	Effect of sleeve gastrectomy on hypertension. <i>Journal of the American Society of Hypertension</i> , 2018, 12, e19-e25.	2.3	13
143	Hormone Replacement Therapy and Stroke: Are the Results Surprising?. <i>Circulation</i> , 2001, 103, 620-622.	1.6	12
144	Ethnicity and Blood Pressure. <i>Journal of Clinical Hypertension</i> , 2005, 7, 357-364.	1.0	12

#	ARTICLE	IF	CITATIONS
145	Targeted delivery of human iPS-ECs overexpressing IL-8 receptors inhibits neointimal and inflammatory responses to vascular injury in the rat. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2016, 310, H705-H715.	1.5	12
146	Distinctive Risk Factors and Phenotype of Younger Patients With Resistant Hypertension. <i>Hypertension</i> , 2017, 69, 827-835.	1.3	12
147	Novel Medical Treatments for Hypertension and Related Comorbidities. <i>Current Hypertension Reports</i> , 2018, 20, 90.	1.5	12
148	Are there meaningful differences in blood pressure control with current antihypertensive agents?. <i>American Journal of Hypertension</i> , 2002, 15, S14-S21.	1.0	11
149	New challenges in blood pressure goals and assessment. <i>Nature Reviews Cardiology</i> , 2011, 8, 73-75.	6.1	11
150	Race and sex differences in ambulatory blood pressure measures among HIV+ adults. <i>Journal of the American Society of Hypertension</i> , 2017, 11, 420-427.e3.	2.3	11
151	Impact of Intensive Versus Standard Blood Pressure Management by Tertiles of Blood Pressure in SPRINT (Systolic Blood Pressure Intervention Trial). <i>Hypertension</i> , 2018, 71, 1064-1074.	1.3	11
152	Moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker monotherapy. <i>Journal of Hypertension</i> , 2011, 29, 161-170.	0.3	10
153	The Matrikine Acetylated Proline-Glycine-Proline Couples Vascular Inflammation and Acute Cardiac Rejection. <i>Scientific Reports</i> , 2017, 7, 7563.	1.6	10
154	Untreated Hypertension and Subsequent Incidence of Colorectal Cancer: Analysis of a Nationwide Epidemiological Database. <i>Journal of the American Heart Association</i> , 2021, 10, e022479.	1.6	10
155	The INTERSTROKE Study: hypertension is by far the most important modifiable risk factor for stroke. <i>Blood Pressure</i> , 2017, 26, 131-132.	0.7	9
156	New data on antihypertensive drugs and risk of cancer: should we worry?. <i>Blood Pressure</i> , 2019, 28, 1-3.	0.7	9
157	Association of Sustained Blood Pressure Control with Multimorbidity Progression Among Older Adults. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 2059-2066.	1.3	9
158	Racial Differences in Blood Pressure Control Following Stroke: The REGARDS Study. <i>Stroke</i> , 2021, 52, 3944-3952.	1.0	9
159	Association of Race/Ethnicity-Specific Changes in Antihypertensive Medication Classes Initiated Among Medicare Beneficiaries With the Eighth Joint National Committee Panel Member Report. <i>JAMA Network Open</i> , 2020, 3, e2025127.	2.8	9
160	Incidence and Outcomes of Acute Heart Failure With Preserved Versus Reduced Ejection Fraction in SPRINT. <i>Circulation: Heart Failure</i> , 2021, 14, CIRCHEARTFAILURE121008322.	1.6	9
161	SPRINT Revisited: Updated Results and Implications. <i>Hypertension</i> , 2021, 78, 1701-1710.	1.3	9
162	Hyperoxia-induced Converting Enzyme Insufficiency in Conscious Rat: Cardiovascular Effects. <i>Experimental Lung Research</i> , 1987, 12, 37-56.	0.5	8

#	ARTICLE	IF	CITATIONS
163	SPS3 Evidence Supports Intensive Blood Pressure Control. <i>Circulation</i> , 2016, 133, 552-554.	1.6	8
164	Worsening Kidney Function Is the Major Mechanism of Heart Failure in Hypertension. <i>JACC: Heart Failure</i> , 2021, 9, 100-111.	1.9	8
165	Masked Uncontrolled Hypertension Is Accompanied by Increased Out-of-Clinic Aldosterone Secretion. <i>Hypertension</i> , 2021, 77, 435-444.	1.3	8
166	Estimated GFR Variability and Risk of Cardiovascular Events and Mortality in SPRINT (Systolic Blood Pressure Treatment Group) Trial. <i>Journal of the American Society of Hypertension</i> , 2021, 12, 101-109.	2.1	10
167	J Curve in Hypertension. <i>Current Cardiovascular Risk Reports</i> , 2012, 6, 281-290.	0.8	7
168	Induced Pluripotent Stem Cell-Derived Endothelial Cells Overexpressing Interleukin-8 Receptors A/B and/or C-C Chemokine Receptors 2/5 Inhibit Vascular Injury Response. <i>Stem Cells Translational Medicine</i> , 2017, 6, 1168-1177.	1.6	7
169	Induced pluripotent stem cell-derived endothelial cells attenuate lipopolysaccharide-induced acute lung injury. <i>Journal of Applied Physiology</i> , 2019, 127, 444-456.	1.2	7
170	Heart Failure Prevention in Older Patients Using Intensive Blood Pressure Reduction. <i>JACC: Heart Failure</i> , 2019, 7, 1032-1041.	1.9	7
171	Clinical characteristics, antihypertensive medication use and blood pressure control among patients with treatment-resistant hypertension. <i>Journal of Hypertension</i> , 2019, 37, 2216-2224.	0.3	7
172	Cuff-less measurements of blood pressure: are we ready for a change?. <i>Blood Pressure</i> , 2021, 30, 205-207.	0.7	7
173	Factors Associated With Not Having a Healthcare Visit in the Past Year Among US Adults With Hypertension: Data From NHANES 2013-2018. <i>American Journal of Hypertension</i> , 2022, 35, 132-141.	1.0	7
174	Using web-based training to improve accuracy of blood pressure measurement among health care professionals: A randomized trial. <i>Journal of Clinical Hypertension</i> , 2022, 24, 255-262.	1.0	7
175	Updated Guidelines for Management of High Blood Pressure in Japan. <i>Hypertension Research</i> , 2014, 37, 484-487.	1.5	6
176	BP Targets in Hypertension: What Should We Do Now That SPRINT Is Out?. <i>Current Cardiology Reports</i> , 2016, 18, 98.	1.3	6
177	Assessment of vascular function in low socioeconomic status preschool children: a pilot study. <i>Journal of the American Society of Hypertension</i> , 2017, 11, 101-109.	2.3	6
178	Obesity-Associated Hypertension: the Upcoming Phenotype in African-American Women. <i>Current Hypertension Reports</i> , 2017, 19, 41.	1.5	6
179	Impact of the SPRINT Trial on Hypertension Management. <i>Annual Review of Medicine</i> , 2018, 69, 81-95.	5.0	6
180	Challenges in oscillometric blood pressure measurement in atrial fibrillation: looking for practical solutions. <i>Blood Pressure</i> , 2018, 27, 1-2.	0.7	6

#	ARTICLE	IF	CITATIONS
181	Lower Blood Pressure Thresholds Raise the Bar in Pregnancy. <i>Circulation Research</i> , 2019, 125, 195-197.	2.0	6
182	Forty-Year Shifting Distribution of Systolic Blood Pressure With Population Hypertension Treatment and Control. <i>Circulation</i> , 2020, 142, 1524-1531.	1.6	6
183	Maintaining Normal Blood Pressure Across the Life Course. <i>Hypertension</i> , 2021, 77, 1490-1499.	1.3	6
184	Reasons for Uncontrolled Blood Pressure Among US Adults: Data From the US National Health and Nutrition Examination Survey. <i>Hypertension</i> , 2021, 78, 1567-1576.	1.3	6
185	Cardiovascular care for older adults: hypertension and stroke in the older adult. <i>Journal of Geriatric Cardiology</i> , 2016, 13, 373-9.	0.2	6
186	Cardiovascular Disease Risk Reduction and Body Mass Index. <i>Current Hypertension Reports</i> , 2022, 24, 535-546.	1.5	6
187	Hypoxia-Induced Oxygen Tolerance: Maintenance of Endothelial Metabolic Function. <i>Experimental Lung Research</i> , 1988, 14, 887-896.	0.5	5
188	Guidelines for Managing High Blood Pressure—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 295.	3.8	5
189	The effects of urate lowering therapy on inflammation, endothelial function, and blood pressure (SURPHER) study design and rationale. <i>Contemporary Clinical Trials</i> , 2016, 50, 238-244.	0.8	5
190	Renal denervation achieved by endovascular delivery of ultrasound in RADIANCE-HTN SOLO or by radiofrequency energy in SPYRAL HTN-OFF and SPYRAL-ON lowers blood pressure. <i>Blood Pressure</i> , 2018, 27, 185-187.	0.7	5
191	Systolic blood pressure control prevents cognitive decline and slows development of white matter lesions in the brain: the SPRINT MIND study outcomes. <i>Blood Pressure</i> , 2019, 28, 356-357.	0.7	5
192	Will we ever use angiotensin receptor neprilysin inhibition (ARNi) for the treatment of hypertension?. <i>Blood Pressure</i> , 2019, 28, 75-76.	0.7	5
193	Heart Failure Primary Prevention: What Does SPRINT Add?: Recent Advances in Hypertension. <i>Hypertension</i> , 2021, 77, 1804-1814.	1.3	5
194	Effect of Intensive versus Standard BP Control on AKI and Subsequent Cardiovascular Outcomes and Mortality: Findings from the SPRINT EHR Study. <i>Kidney360</i> , 2022, 3, 1253-1262.	0.9	5
195	Lung MK 351A uptake after hypoxia adaptation and subsequent hyperoxia exposure. <i>Lung</i> , 1988, 166, 209-219.	1.4	4
196	Novel strategies for treatment of resistant hypertension. <i>Kidney International Supplements</i> , 2013, 3, 357-363.	4.6	4
197	Masked Hypertension. <i>Current Hypertension Reports</i> , 2017, 19, 81.	1.5	4
198	Sprinting Toward the Optimal Blood Pressure Target for Hypertensive Patients. <i>Circulation Research</i> , 2018, 123, 531-534.	2.0	4

#	ARTICLE	IF	CITATIONS
199	What is the first choice for blood pressure treatment?. <i>Lancet, The</i> , 2019, 394, 1782-1784.	6.3	4
200	The five RADIANCE-HTN and SPYRAL-HTN randomised studies suggest that the BP lowering effect of RDN corresponds to the effect of one antihypertensive drug. <i>Blood Pressure</i> , 2021, 30, 327-331.	0.7	4
201	Racial Differences in XO (Xanthine Oxidase) and Mitochondrial DNA Damage-Associated Molecular Patterns in Resistant Hypertension. <i>Hypertension</i> , 2022, 79, 775-784.	1.3	4
202	Depressive Symptoms and Incident Hospitalization for Heart Failure: Findings From the REGARDS Study. <i>Journal of the American Heart Association</i> , 2022, 11, e022818.	1.6	4
203	Pet Ownership and the Risk of Arterial Hypertension and Cardiovascular Disease. <i>Current Hypertension Reports</i> , 2022, 24, 295-302.	1.5	4
204	Age-Dependent Relationship of Hypertension Subtypes With Incident Heart Failure. <i>Journal of the American Heart Association</i> , 2022, 11, e025406.	1.6	4
205	Dietary NaCl Loading Enhances Antihypertensive Effect of Guanabenz in Spontaneously Hypertensive Rats. <i>American Journal of Hypertension</i> , 1989, 2, 435-439.	1.0	3
206	Cardiac renin angiotensin system in hypertrophy and the progression to heart failure. <i>Heart Failure Reviews</i> , 1996, 1, 63-72.	1.7	3
207	The polypill: an emerging treatment alternative for secondary prevention of cardiovascular disease. <i>Blood Pressure</i> , 2016, 25, 276-279.	0.7	3
208	Baseline Quality of Life and Risk of Stroke in the ALLHAT Study (Antihypertensive and Lipid-Lowering) Tj ETQq0 0 0 rBT /Overlock 10 Tf	1.0	3
209	What is the most appropriate target SBP in persons with hypertension and diabetes mellitus?. <i>Journal of Hypertension</i> , 2018, 36, 37-40.	0.3	3
210	The PARAGON Heart Failure trial – ongoing investigation of the angiotensin receptor antagonist/nepriylsin inhibitor sacubitril/valsartan in heart failure patients with hypertension and preserved ejection fraction. <i>Blood Pressure</i> , 2019, 28, 215-216.	0.7	3
211	Medication-Na ⁺ ve Blood Pressure and Incident Cancers: Analysis of 2 Nationwide Population-Based Databases. <i>American Journal of Hypertension</i> , 2022, 35, 731-739.	1.0	3
212	What Is or What Is Not a Risk Factor for Arterial Hypertension? Not Hamlet, but Medical Students Answer That Question. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 8206.	1.2	3
213	The INTERSALT Study and the complex relationship between salt intake and blood pressure. <i>Blood Pressure</i> , 2017, 26, 65-66.	0.7	2
214	Renal denervation in hypertension: is it the end or the beginning of a SPYRAL?. <i>Blood Pressure</i> , 2017, 26, 319-320.	0.7	2
215	Treatment strategies for comorbid conditions lower residual risk in patients with treated hypertension: FOURIER and other randomized outcome trials. <i>Blood Pressure</i> , 2017, 26, 257-258.	0.7	2
216	Take a Blood Pressure Pill or Benefit from Renal Denervation?. <i>European Heart Journal</i> , 2018, 39, 3010-3012.	1.0	2

#	ARTICLE	IF	CITATIONS
217	The International Society of Hypertension Guidelines 2020 “ a new drug treatment recommendation in the wrong direction?. Blood Pressure, 2020, 29, 264-266.	0.7	2
218	Was it optimal to drop a diuretic as a first-line choice of drug treatment in the 2020 International Society of Hypertension Guidelines?. Blood Pressure, 2020, 29, 341-343.	0.7	2
219	Aortic blood pressure and arterial stiffness in patients with controlled resistant and non-resistant hypertension. Journal of Clinical Hypertension, 2020, 22, 167-173.	1.0	2
220	Association of Sustained Blood Pressure Control with Lower Risk for High-Cost Multimorbidities Among Medicare Beneficiaries in ALLHAT. Journal of General Internal Medicine, 2021, 36, 2221-2229.	1.3	2
221	Effect of Intensive Versus Standard Blood Pressure Control on Stroke Subtypes. Hypertension, 2021, 77, 1391-1398.	1.3	2
222	Treatment of early hypertension among persons living with HIV in Haiti: Protocol for a randomized controlled trial. PLoS ONE, 2021, 16, e0254740.	1.1	2
223	Kidney Disease, Hypertension Treatment, and Cerebral Perfusion and Structure. American Journal of Kidney Diseases, 2022, 79, 677-687.e1.	2.1	2
224	Blood pressure medication should not be routinely dosed at bedtime. We must disregard the data from the HYGIA project. Journal of Hypertension, 2020, Publish Ahead of Print, .	0.3	2
225	Fibroblast growth factor upregulates periostin and osteopontin expression via distinct signaling pathways in rat pulmonary arterial smooth muscle cells. American Journal of Hypertension, 2004, 17, S172.	1.0	1
226	Does improving hypertension control involve more than just pills?. Nature Clinical Practice Cardiovascular Medicine, 2007, 4, 182-183.	3.3	1
227	Renin Inhibitors in the Management of Hypertension. Journal of Clinical Hypertension, 2007, 9, 706-707.	1.0	1
228	Can Catheter-Based Renal Denervation Be Used Safely and Effectively to Substantially Reduce Blood Pressure in Treatment-Resistant Hypertensive Patients?. Current Cardiology Reports, 2011, 13, 478-480.	1.3	1
229	HOPE-3 and SPRINT: two landmark trials with different outcomes?. Journal of the American Society of Hypertension, 2016, 10, 477-481.	2.3	1
230	Hypertension and Its Complications in a Young Man With Autoimmune Disease. Hypertension, 2017, 69, 536-544.	1.3	1
231	123I-mIBG scintigraphy: Clinical tool for assessing renal sympathetic activity?. Journal of Nuclear Cardiology, 2017, 24, 372-376.	1.4	1
232	Reply. Journal of Hypertension, 2018, 36, 1423-1424.	0.3	1
233	Revisiting ASCOT 16 years later. Lancet, The, 2018, 392, 1092-1094.	6.3	1
234	Case of Episodic and Positional Hypertension. Hypertension, 2020, 76, 614-621.	1.3	1

#	ARTICLE	IF	CITATIONS
235	Global Blood Pressure Screening. <i>Hypertension</i> , 2020, 76, 318-320.	1.3	1
236	Nocturnal blood pressure dipping in treated hypertensives: insights from the SPRINT trial. <i>European Journal of Preventive Cardiology</i> , 2022, 29, e25-e28.	0.8	1
237	What is the association of renin-angiotensin-aldosterone system inhibitors with COVID-19 outcomes: retrospective study of racially diverse patients?. <i>BMJ Open</i> , 2022, 12, e053961.	0.8	1
238	Case study. <i>American Journal of Hypertension</i> , 1998, 11, 192S-194S.	1.0	0
239	Estrogen attenuates inflammatory mediator mRNA expression in balloon injured rat carotid arteries. <i>American Journal of Hypertension</i> , 2004, 17, S242.	1.0	0
240	Estrogenic vasoprotection is lost in aged rats. <i>American Journal of Hypertension</i> , 2004, 17, S244-S245.	1.0	0
241	A STITCH Saves Time and Lowers Blood Pressure. <i>Current Hypertension Reports</i> , 2010, 12, 146-148.	1.5	0
242	Update on Clinical Guidelines for Treatment of Hypertension. <i>Current Cardiovascular Risk Reports</i> , 2014, 8, 1.	0.8	0
243	Blood Pressure in 2016: increased impact factor and change of editors. <i>Blood Pressure</i> , 2016, 25, 331-332.	0.7	0
244	Final Farewell to Alberto Zanchetti MD. <i>European Heart Journal</i> , 2018, 39, 2616-2617.	1.0	0
245	The PARAGON-Heart failure trial – another disappointment for heart failure patients with hypertension and preserved ejection fraction. <i>Blood Pressure</i> , 2019, 28, 276-278.	0.7	0
246	Need for multiple risk reduction strategies in clinical trials enrolling high risk patients - FOURIER investigating PCSK-9 inhibitor to lower cholesterol revisited. <i>Blood Pressure</i> , 2019, 28, 144-145.	0.7	0
247	State of the Art: the Not-So-Great Wall of America. <i>Current Hypertension Reports</i> , 2019, 21, 97.	1.5	0
248	The AJMS Celebrates # 200!. <i>American Journal of the Medical Sciences</i> , 2020, 359, 61-62.	0.4	0
249	The Health Outcomes Prevention and Evaluation 4 (HOPE 4) project: A successful community-based intervention to lower cardiovascular risk in people with hypertension. <i>Blood Pressure</i> , 2020, 29, 1-2.	0.7	0
250	Intensive systolic blood pressure control and prevention of new onset atrial fibrillation in the SPRINT study: is the association really controversial?. <i>Blood Pressure</i> , 2020, 29, 199-201.	0.7	0
251	How to deal with the occurrence of rare drug-induced adverse events: the example of sprue-like enteropathy induced by olmesartan medoxomil and other angiotensin-receptor blockers. <i>Blood Pressure</i> , 2020, 29, 68-69.	0.7	0
252	Blood pressure target in patients with hypertension and type-2 diabetes older than 65 years. Is $130/80\text{ mmHg}$ the right target or an excessive objective preventing from achieving the clinical goals we are aiming at?. <i>Blood Pressure</i> , 2021, 30, 79-81.	0.7	0

#	ARTICLE	IF	CITATIONS
253	Response to “Comment” on the Story of the Silent Killer, a History of Hypertension: Its Discovery, Diagnosis, Treatment, and Debate. Current Hypertension Reports, 2021, 23, 7.	1.5	0
254	Better drug adherence improves blood pressure control and lowers cardiovascular disease outcomes “ from single pill combinations to monitoring of a nationwide health insurance database. Blood Pressure, 2021, 30, 1-2.	0.7	0
255	Combining proteomics, home blood pressure telemonitoring and patient empowerment to improve cardiovascular and renal protection. Blood Pressure, 2021, 30, 267-268.	0.7	0
256	Mechanisms of Glucosamine-Mediated Relaxing Responses in Isolated Rat Aortic Rings. FASEB Journal, 2011, 25, 1020.4.	0.2	0
257	Thirty years with LIFE—a randomized clinical trial with more than 200 published articles on clinical aspects of left ventricular hypertrophy. Blood Pressure, 2022, 31, 125-128.	0.7	0